STI Stock Trade Intelligence
ENP

Entropy Neurodynamics Ltd

Health Care · ASX:ENP
$0.0270
▼ -6.90%
Market cap
$44M
Turnover
$107,422
Last price
$0.0270
Day change
-6.90%
Announcements
20
Range, past year
Open 0.033 · Low 0.025 · Now 0.027 · High 0.043
Open ENP in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ENP momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
23/100
Wyckoff phase
Accumulation6d
Trend stage
Neutral
1 Day
-6.9%
1 Week
-6.9%
1 Month
-22.9%
RSI
29
Avg daily range
6.2%

Entropy Neurodynamics Ltd scores 23 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 6 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.84 — highly linear uptrend
Points to watch
  • RSI oversold (29)
  • 60d drawdown -35.7%
  • High volatility (ATR 6.2%)
  • Risk rating: Very High
  • Composite downside risk elevated
ENP appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ENP announcements

Recent price-sensitive releases.
  • 2026-10-28 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-07 TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study Progress Report
  • 2026-09-14 All Patients Improve, 50% Achieve 12-Week BED Remission Progress Report
  • 2026-08-28 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-26 Entropy Advances TRP-8803 to US Phase 2 in Depression Web Cast | Trading Halt Lifted | Progress Report
  • 2026-08-24 Trading Halt Trading Halt
  • 2026-08-19 TRP 8803 manufacturing secured for Phase 2/3 advancement Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.